208 related articles for article (PubMed ID: 27516099)
1. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly.
Shen M; Zhang Q; Liu W; Wang M; Zhu J; Ma Z; He W; Li S; Shou X; Li Y; Zhang Z; Ye H; He M; Lu B; Yao Z; Lu Y; Qiao N; Ye Z; Zhang Y; Yang Y; Zhao Y; Wang Y
Neuroradiology; 2016 Nov; 58(11):1057-1065. PubMed ID: 27516099
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.
Heck A; Emblem KE; Casar-Borota O; Bollerslev J; Ringstad G
Endocrine; 2016 May; 52(2):333-43. PubMed ID: 26475495
[TBL] [Abstract][Full Text] [Related]
3. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
[TBL] [Abstract][Full Text] [Related]
4. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI.
Kocak B; Durmaz ES; Kadioglu P; Polat Korkmaz O; Comunoglu N; Tanriover N; Kocer N; Islak C; Kizilkilic O
Eur Radiol; 2019 Jun; 29(6):2731-2739. PubMed ID: 30506213
[TBL] [Abstract][Full Text] [Related]
5. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly.
Wang M; Shen M; He W; Yang Y; Liu W; Lu Y; Ma Z; Ye Z; Zhang Y; Zhao X; Lu B; Hu J; Huang Y; Shou X; Wang Y; Ye H; Li Y; Li S; Zhao Y; Zhang Z
Endocr J; 2016 Sep; 63(9):819-834. PubMed ID: 27432816
[TBL] [Abstract][Full Text] [Related]
6. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas.
Hu J; Yan J; Zheng X; Zhang Y; Ran Q; Tang X; Shu T; Shen R; Duan L; Zhang D; Guo Q; Zhang W; Yang H; Li S
J Endocrinol Invest; 2019 Apr; 42(4):443-451. PubMed ID: 30171531
[TBL] [Abstract][Full Text] [Related]
9. Added Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Response to Somatostatin Analogs in Acromegaly Patients.
Durmaz ES; Kocak B; Kadioglu P; Comunoglu N; Ulu MO; Kocer N; Islak C; Kizilkilic O
Turk Neurosurg; 2019; 29(6):835-842. PubMed ID: 30900736
[TBL] [Abstract][Full Text] [Related]
10. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly.
Heck A; Emblem KE; Casar-Borota O; Ringstad G; Bollerslev J
Endocrine; 2016 Jul; 53(1):327-30. PubMed ID: 26615593
[No Abstract] [Full Text] [Related]
11. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.
Gatto F; Biermasz NR; Feelders RA; Kros JM; Dogan F; van der Lely AJ; Neggers SJ; Lamberts SW; Pereira AM; Ferone D; Hofland LJ
Eur J Endocrinol; 2016 May; 174(5):651-62. PubMed ID: 26888629
[TBL] [Abstract][Full Text] [Related]
12. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: A hospital-based study of 237 cases.
Shen M; Yang Y; He W; Qiao N; He M; Shou X; Wang M; Ma Z; Ye Z; Zhang Y; Chen Z; Zhang Q; Zhou X; Cao X; Ye H; Wang Y; Li S; Li Y; Zhao Y; Zhang Z
Growth Horm IGF Res; 2020 Dec; 55():101354. PubMed ID: 33011455
[TBL] [Abstract][Full Text] [Related]
14. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
[TBL] [Abstract][Full Text] [Related]
15. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
Heck A; Ringstad G; Fougner SL; Casar-Borota O; Nome T; Ramm-Pettersen J; Bollerslev J
Clin Endocrinol (Oxf); 2012 Jul; 77(1):72-8. PubMed ID: 22066905
[TBL] [Abstract][Full Text] [Related]
16. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly.
Luo M; Yu J; Tang R
J Neurooncol; 2024 May; 167(3):415-425. PubMed ID: 38441839
[TBL] [Abstract][Full Text] [Related]
17. Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas.
Tortora F; Negro A; Grasso LFS; Colao A; Pivonello R; Splendiani A; Brunese L; Caranci F
Gland Surg; 2019 Sep; 8(Suppl 3):S150-S158. PubMed ID: 31559182
[TBL] [Abstract][Full Text] [Related]
18. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
[TBL] [Abstract][Full Text] [Related]
19. Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD; Tabarin A; Vasiljevic A; Bonneville JF; Moreau-Grangé L; Schillo F; Delemer B; Barlier A; Figarella-Branger D; Bisot-Locard S; Santos A; Chanson P; Raverot G
J Clin Endocrinol Metab; 2022 Nov; 107(11):2982-2991. PubMed ID: 36136828
[TBL] [Abstract][Full Text] [Related]
20. PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE.
Ezzat S; Caspar-Bell GM; Chik CL; Denis MC; Domingue MÈ; Imran SA; Johnson MD; Lochnan HA; Grégoire Nyomba BL; Prebtani A; Ridout R; Ramirez JAR; Van Uum S
Endocr Pract; 2019 Apr; 25(4):379-393. PubMed ID: 30657362
[No Abstract] [Full Text] [Related]
[Next] [New Search]